Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT03483948 Terminated - Clinical trials for Acute Myeloid Leukemia

Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

Start date: October 9, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, non-randomized, multicenter study to evaluate the safety, pharmacokinetics and preliminary efficacy of HMPL-523 in combination with Azacitidine in previously untreated elderly patients with AML who are not eligible for standard induction therapy.

NCT ID: NCT03473457 Terminated - Clinical trials for Relapsed/Refractory Acute Myeloid Leukemia(AML)

CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia

AML
Start date: April 1, 2018
Phase: N/A
Study type: Interventional

Acute myeloid leukemia (AML) is a group of genetically highly heterogeneous malignant disease . The disease is the most common type of adult acute leukemia. Overall survival (OS) was less than 50% in 5 years. Chimeric Antigen Receptor-transduced T cell (CAR-T) therapy is one of revolutionary targeted immunotherapy. The efficacy of CAR-T cells for the treatment of acute B lymphocytic leukemia has been widely recognized, although it start late, several clinical trials have been register in ClinicalTrials.gov.

NCT ID: NCT03465540 Terminated - Multiple Myeloma Clinical Trials

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Start date: August 17, 2018
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.

NCT ID: NCT03410407 Terminated - Clinical trials for Acute Myeloid Leukemia

Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)

AML1617
Start date: March 19, 2019
Phase:
Study type: Observational

The present study aims at evaluating the prognostic factors at diagnosis predicting Central Nervous System (CNS) relapse in order to identify a group of patients with higher risk of CNS involvement in which prophylaxis with liposomal Ara-C or other drugs should be indicated.

NCT ID: NCT03381118 Terminated - Clinical trials for Acute Myeloid Leukemia

Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients

Start date: June 30, 2017
Phase: Phase 2
Study type: Interventional

A phase II trial to compare the efficacy and safety of nivolumab and intermediate dose cytarabine with or without haploidentical lymphocyte infusion. To identify the role of haploidentical lymphocytes in the treatment of acute myeloid leukemia in older adults. The patients will be stratified based on the remission number (first or second)

NCT ID: NCT03360006 Terminated - Clinical trials for Acute Myeloid Leukemia (AML)

A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer

Start date: March 16, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase 1, dose-escalation (Segment 1) and expansion (Segment 2) study to determine the maximum tolerated dose (MTD) and/or the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-744 in participants with relapsed/refractory Acute Myeloid Leukemia (AML).

NCT ID: NCT03301597 Terminated - Clinical trials for Leukemia, Myeloid, Acute

NLA101 in Adults Receiving High Dose Chemotherapy for AML

LAUNCH
Start date: January 24, 2018
Phase: Phase 2
Study type: Interventional

Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML.

NCT ID: NCT03290664 Terminated - Clinical trials for Acute Myelogenous Leukemia

CD3-/CD19- vs CD3-/CD56+ Haplo NK for AML Pts Who Failed 1-2 Inductions

Start date: October 18, 2017
Phase: Phase 2
Study type: Interventional

This is a phase II trial of related donor HLA-haploidentical NK-cell based therapy for the treatment of newly diagnosed acute myelogenous leukemia (AML) (except acute promyelocytic leukemia) in persons who failed to achieve a complete remission (CR) after one or two standard induction attempts. Failure is defined as ≥ 30% bone marrow blasts in a bone marrow of at least 20% cellularity at the mid-cycle (~day 14) bone marrow biopsy or residual AML on ~day 28 bone marrow biopsy by morphology, flow, PCR or FISH.

NCT ID: NCT03272633 Terminated - Clinical trials for Acute Lymphoblastic Leukemia

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Start date: October 26, 2020
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant.

NCT ID: NCT03233074 Terminated - Clinical trials for Acute Myeloid Leukemia

Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors

COSMOS
Start date: November 17, 2017
Phase:
Study type: Observational

It is of clinical significance to better characterize the intrinsic defects harbored by mesenchymal stromal cells (MSC) in Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) context, as compared to physiological conditions. Such research initiative aims to dissect the cross-talk between malignant hematopoietic stem cells (HSC) and their bone marrow (BM) partners in crime, further prospecting for innovative stromal-directed strategies for the treatment of Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).